THE CHALLENGING ISSUES, DIAGNOSIS AND TREATMENT OF MUCORMYCOSIS-A NARRATIVE REVIEW

Mucormycosis is a new fungal disease that increased the morbidity and mortality rate in this present scenario. It’s difficult to diagnose and cure due to proper scientific evidence is not yet being designed. The disease’s prevalence appears to be rising. In high-income nations, hematological malignancies are the most prevalent underlying illness, while uncontrolled diabetes is usually linked to pulmonary mucormycosis in low-income nations. Mucormycetes can be detected or identified using histopathology and molecular tests, and they can be recommended as important add-on techniques to augment standard diagnostic techniques. Reversal of underlying predisposing factors, early delivery of active antifungal medications at the appropriate dosage, thorough excision of all diseased tissues and different adjuvant treatments are all part of a successful therapy strategy mucormycosis. Liposomal amphotericin B antifungal medications have been added to our antifungal arsenal, but amphotericin B remains the medication of choice for first antifungal therapy. Despite attempts to better understand the pathophysiology of mucormycosis, early diagnosis and intensive treatment, the disease’s fatality rate remains high.